Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Assets (2016 - 2026)

Summit Therapeutics filings provide 13 years of Assets readings, the most recent being $647.9 million for Q1 2026.

  • Quarterly Assets rose 68.79% to $647.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $647.9 million through Mar 2026, up 68.79% year-over-year, with the annual reading at $751.2 million for FY2025, 72.46% up from the prior year.
  • Assets hit $647.9 million in Q1 2026 for Summit Therapeutics, down from $751.2 million in the prior quarter.
  • Across five years, Assets topped out at $751.2 million in Q4 2025 and bottomed at $95.7 million in Q2 2022.
  • Average Assets over 5 years is $339.5 million, with a median of $261.7 million recorded in 2025.
  • The largest annual shift saw Assets skyrocketed 485.82% in 2022 before it plummeted 69.44% in 2023.
  • Summit Therapeutics' Assets stood at $664.2 million in 2022, then plummeted by 69.44% to $202.9 million in 2023, then skyrocketed by 114.62% to $435.6 million in 2024, then soared by 72.46% to $751.2 million in 2025, then dropped by 13.76% to $647.9 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Assets are $647.9 million (Q1 2026), $751.2 million (Q4 2025), and $261.7 million (Q3 2025).